LONDON, April 25 (Reuters) - GlaxoSmithKline's chiefexecutive said on Wednesday she had no interest in acquiringShire, the London-listed rare diseases specialist thatTakeda Pharmaceutical hopes to buy for some $64billion.
Emma Walmsley, speaking to reporters after first-quarterresults, said the British drugmaker's focus was on deals toacquire early-stage experimental drugs that would help rebuildthe company's pharmaceuticals pipeline.(Reporting by Ben Hirschler; editing by Jason Neely)